Eton Pharmaceuticals (NASDAQ:ETON) Shares Gap Up After Better-Than-Expected Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) gapped up before the market opened on Friday following a better than expected earnings announcement. The stock had previously closed at $47.15, but opened at $58.59. Eton Pharmaceuticals shares last traded at $52.2910, with a volume of 215,792 shares changing hands.

The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.19. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. The firm had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million.

Key Headlines Impacting Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record Q3 product sales reached $57.9 million, up 158% year over year. Eton said it exceeded its $200 million annualized revenue run-rate goal five quarters ahead of schedule. Eton Q3 2026 financial results
• Positive Sentiment: The company raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to more than 40%, from more than 35%. Q3 adjusted EBITDA was $28.5 million, or 49% of revenue. Eton Q3 2026 financial results
• Positive Sentiment: Q3 fully diluted GAAP EPS was $1.06, versus the Zacks consensus estimate of $0.34; non-GAAP fully diluted EPS was $0.50. Revenue also exceeded analyst expectations of about $42 million. Eton Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management highlighted growth and rare-disease pipeline progress, including preliminary ET-700 pilot-study results assessing copper absorption inhibition and gastrointestinal tolerability. The available report details do not specify the study findings. ET-700 pilot study announcement

Analyst Ratings Changes

Several research firms recently issued reports on ETON. Zacks Research raised Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. HC Wainwright boosted their price target on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday. Craig Hallum reaffirmed a “buy” rating and set a $78.00 price target on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. Finally, Canaccord Genuity Group increased their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $74.00.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Krempa sold 4,166 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the sale, the insider owned 43,381 shares of the company’s stock, valued at approximately $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 79,166 shares of company stock worth $4,809,672 in the last 90 days. 16.49% of the stock is currently owned by corporate insiders.

Institutional Trading of Eton Pharmaceuticals

Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in Eton Pharmaceuticals in the second quarter valued at about $68,629,000. EcoR1 Capital LLC boosted its position in Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals in the second quarter worth about $42,569,426. Pillsbury Lake Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $14,015,083. Finally, Panoramic Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at about $7,537,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Up 13.0%

The stock has a market cap of $1.52 billion, a PE ratio of 140.19 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. The company’s 50-day moving average price is $54.92 and its 200 day moving average price is $36.26.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.